Targeting upstream alarmins—through agents such as itepekimab (anti-IL-33) and anti-TSLP antibodies—shows promise in mitigating tissue eosinophilia and broad inflammatory cascades before they fully develop. The gene discussed is TSLP; the disease is Increased total eosinophil count.